Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM: Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
NCT07419880Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium cromoglycate in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
sodium cromoglycate
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07419880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07419880.